IRIS UniCatt

Pera, Maria Carmela
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.005
AS - Asia 4.195
EU - Europa 3.941
SA - Sud America 819
Continente sconosciuto - Info sul continente non disponibili 165
AF - Africa 115
OC - Oceania 11
Totale 16.251
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.688
SG - Singapore 1.980
IT - Italia 949
CN - Cina 843
DE - Germania 826
BR - Brasile 657
SE - Svezia 442
NL - Olanda 415
VN - Vietnam 366
FR - Francia 339
IE - Irlanda 221
GB - Regno Unito 193
IN - India 153
CA - Canada 150
JP - Giappone 150
ID - Indonesia 112
BD - Bangladesh 106
HK - Hong Kong 100
RU - Federazione Russa 98
FI - Finlandia 90
KR - Corea 68
TR - Turchia 61
MX - Messico 60
AR - Argentina 56
PL - Polonia 56
ES - Italia 53
IQ - Iraq 49
UA - Ucraina 38
CO - Colombia 32
IL - Israele 32
ZA - Sudafrica 30
BE - Belgio 26
AT - Austria 25
CZ - Repubblica Ceca 25
PK - Pakistan 24
LT - Lituania 22
EC - Ecuador 21
CH - Svizzera 20
VE - Venezuela 19
PA - Panama 18
SA - Arabia Saudita 18
IR - Iran 17
JM - Giamaica 16
PH - Filippine 16
RO - Romania 16
MA - Marocco 14
PT - Portogallo 14
EG - Egitto 13
MK - Macedonia 13
JO - Giordania 12
TN - Tunisia 12
AE - Emirati Arabi Uniti 11
CI - Costa d'Avorio 11
HN - Honduras 11
RS - Serbia 11
UZ - Uzbekistan 11
CR - Costa Rica 10
KE - Kenya 9
PY - Paraguay 9
TH - Thailandia 9
NI - Nicaragua 8
SV - El Salvador 8
UY - Uruguay 8
EE - Estonia 7
NP - Nepal 7
OM - Oman 7
AL - Albania 6
BG - Bulgaria 6
KZ - Kazakistan 6
MY - Malesia 6
PE - Perù 6
AU - Australia 5
CL - Cile 5
DK - Danimarca 5
DO - Repubblica Dominicana 5
GP - Guadalupe 5
GT - Guatemala 5
HR - Croazia 5
SN - Senegal 5
TT - Trinidad e Tobago 5
AZ - Azerbaigian 4
BO - Bolivia 4
GR - Grecia 4
KG - Kirghizistan 4
LU - Lussemburgo 4
NZ - Nuova Zelanda 4
BH - Bahrain 3
BY - Bielorussia 3
DZ - Algeria 3
LK - Sri Lanka 3
LY - Libia 3
NG - Nigeria 3
PR - Porto Rico 3
BB - Barbados 2
BS - Bahamas 2
BT - Bhutan 2
CW - ???statistics.table.value.countryCode.CW??? 2
DM - Dominica 2
GE - Georgia 2
HT - Haiti 2
Totale 16.045
Salva come PNG Salva come JPEG
Città #
Singapore 1.171
Ashburn 859
San Jose 696
Chandler 461
Amsterdam 368
Frankfurt am Main 279
Los Angeles 263
New York 242
Rome 225
Dublin 201
Hefei 182
Tukwila 151
Beijing 144
Council Bluffs 140
Tokyo 140
Milan 135
Ho Chi Minh City 120
Jakarta 101
Lauterbourg 99
Hanoi 93
Hong Kong 88
Dallas 85
Chicago 80
Santa Clara 77
São Paulo 68
Boston 67
Seoul 66
Munich 65
Atlanta 62
Kent 53
Buffalo 52
North Bergen 52
Helsinki 50
The Dalles 48
Marseille 47
Montreal 43
Orem 42
Moscow 41
Phoenix 40
Pune 38
San Mateo 38
Toronto 37
Warsaw 37
Princeton 36
Boardman 35
London 35
Denver 33
Paris 33
Brooklyn 32
Nuremberg 32
Houston 30
Palermo 25
Rio de Janeiro 24
Chennai 23
San Francisco 23
Poplar 22
Ann Arbor 21
Baghdad 21
Johannesburg 21
Mexico City 21
Shanghai 21
Stockholm 21
Wilmington 21
Dearborn 20
Jacksonville 20
Seattle 20
Turin 20
Belo Horizonte 19
Brussels 19
Düsseldorf 18
Nanjing 18
Bologna 17
Bremen 17
Da Nang 17
Naples 17
Ankara 16
Brno 16
Columbus 16
Haiphong 16
Turku 16
Bari 15
Charlotte 15
Hyderabad 15
Lappeenranta 15
Falkenstein 14
Agrolândia 13
Brasília 13
Carrboro 13
Amman 12
Augusta 12
Bexley 12
Las Vegas 12
Portsmouth 12
St Louis 12
Vienna 12
Abidjan 11
Biên Hòa 11
Cattolica 11
Cincinnati 11
Pittsburgh 11
Totale 8.430
Salva come PNG Salva come JPEG
Nome #
Revised upper limb module in type II and III spinal muscular atrophy: 24-month changes 1.055
Predictive models in SMA II natural history trajectories using machine learning: A proof of concept study 369
Body mass index in type 2 spinal muscular atrophy: a longitudinal study 332
Myostatin Levels in SMA Following Disease-Modifying Treatments: A Multi-Center Study 323
Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial 322
Longitudinal natural history of type I spinal muscular atrophy: A critical review 281
Assessing floppy infants: a new module 235
Oral and Swallowing Abilities Tool (OrSAT) in nusinersen treated patients 225
Neurological assessment of newborns with spinal muscular atrophy identified through neonatal screening 205
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial 204
Developmental milestones in type I spinal muscular atrophy 197
Prevalence of Spinal Muscular Atrophy in the Era of Disease-Modifying Therapies: An Italian Nationwide Survey 192
Type I SMA “new natural history”: long-term data in nusinersen-treated patients 187
Clinical phenotypes and trajectories of disease progression in type 1 spinal muscular atrophy 186
SMA-miRs (MiR-181a- 5p, -324-5p, and -451a) are overexpressed in spinal muscular atrophy skeletal muscle and serum samples 183
Onasemnogene abeparvovec in spinal muscular atrophy: predictors of efficacy and safety in naïve patients with spinal muscular atrophy and following switch from other therapies 182
SMA-miRs (MiR-181a- 5p, -324-5p, and -451a) are overexpressed in spinal muscular atrophy skeletal muscle and serum samples 180
Early neurological signs in infants identified through neonatal screening for SMA: do they predict outcome? 176
Different trajectories in upper limb and gross motor function in spinal muscular atrophy 176
Age related treatment effect in type II Spinal Muscular Atrophy pediatric patients treated with nusinersen 171
Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls 170
Sometimes they come back: New and old spinal muscular atrophy adults in the era of nusinersen 168
Risdiplam in types 2 and 3 spinal muscular atrophy: A randomised, placebo-controlled, dose-finding trial followed by 24 months of treatment 165
Predominant distal muscle involvement in spinal muscular atrophy 164
Cardiac Function in Types II and III Spinal Muscular Atrophy: Should We Change Standars of Care? 163
Long-term progression in type II spinal muscular atrophy: A retrospective observational study 162
6MWT can identify type 3 SMA patients with neuromuscular junction dysfunction 160
Type I spinal muscular atrophy and disease modifying treatments: a nationwide study in children born since 2016 159
The Spinal Muscular Atrophy Health Index: Italian validation of a disease-specific outcome measure 158
Revised north star ambulatory assessment for young boys with Duchenne muscular dystrophy 157
Early treatment of type II SMA slows rate of progression of scoliosis 156
Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls 155
High Expression of SMN circ4-2b-3 in SMA I Children Treated with Nusinersen is Associated with Improved Motor Outcomes 155
Prevalence of Spinal Muscular Atrophy in the Era of Disease-Modifying Therapies: An Italian Nationwide Survey 154
Ambulatory function in spinal muscular atrophy: Age-related patterns of progression. 154
Revised upper limb module for spinal muscular atrophy: Development of a new module 152
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial 151
Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial 148
MRI patterns of muscle involvement in type 2 and 3 spinal muscular atrophy patients 146
Nusinersen efficacy data for 24-month in type 2 and 3 spinal muscular atrophy 146
Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls 145
A critical review of patient and parent caregiver oriented tools to assess health-related quality of life, activity of daily living and caregiver burden in spinal muscular atrophy 144
Nusinersen in pediatric and adult patients with type III spinal muscular atrophy 143
Body mass index in type 2 spinal muscular atrophy: a longitudinal study 143
Age, corticosteroid treatment and site of mutations affect motor functional changes in young boys with Duchenne Muscular Dystrophy 140
Communicative development inventory in type 1 and presymptomatic infants with spinal muscular atrophy: a cohort study 140
Respiratory Needs in Patients with Type 1 Spinal Muscular Atrophy Treated with Nusinersen 139
Content validity and clinical meaningfulness of the HFMSE in spinal muscular atrophy 138
Determining minimal clinically important differences in the Hammersmith Functional Motor Scale Expanded for untreated spinal muscular atrophy patients: An international study 135
Patterns of disease progression in type 2 and 3 SMA: Implications for clinical trials 135
New therapies for spinal muscular atrophy: where we stand and what is next 134
Long‐term natural history in type II and III spinal muscular atrophy: a 4‐year international study on the Hammersmith Functional Motor Scale Expanded 132
Revised upper limb module for spinal muscular atrophy: Development of a new module 132
Clinical Variability in Spinal Muscular Atrophy Type III. 132
Sleep disorders in spinal muscular atrophy 130
Clinical Phenotype of Pediatric and Adult Patients With Spinal Muscular Atrophy With Four SMN2 Copies: Are They Really All Stable? 130
Does albuterol have an effect on neuromuscular junction dysfunction in spinal muscular atrophy? 130
Motor function in type 2 and 3 SMA patients treated with Nusinersen: a critical review and meta-analysis 126
An observational study of functional abilities in infants, children, and adults with type 1 SMA 125
Developmental milestones in type I spinal muscular atrophy 124
Development of an academic disease registry for spinal muscular atrophy 123
Risdiplam in Type 1 Spinal Muscular Atrophy 118
Correction to: Risdiplam in Patients Previously Treated with Other Therapies for Spinal Muscular Atrophy: An Interim Analysis from the JEWELFISH Study (Neurology and Therapy, (2023), 12, 2, (543-557), 10.1007/s40120-023-00444-1) 117
Changes in abilities over the initial 12 months of nusinersen treatment for type II SMA 117
Long-term progression in type II spinal muscular atrophy: A retrospective observational study 117
Motor function in type 2 and 3 SMA patients treated with Nusinersen: a critical review and meta-analysis 116
Long-term evolution of neuropsychological competences in encephalopathy with status epilepticus during sleep: a variable prognosis 113
Long term follow-up of scoliosis progression in type II SMA patients 112
Gain and loss of abilities in type II SMA: A 12-month natural history study 112
Profile of cognitive abilities in spinal muscular atrophy type II and III: what is the role of motor impairment? 111
An observational study of functional abilities in infants, children, and adults with type 1 SMA 110
Prognostic factors for tube feeding in type I SMA patients treated with disease-modifying therapies: a cohort study 109
Upper limb function changes over 12 months in untreated SMA II and III individuals: an item-level analysis using the Revised Upper Limb Module 109
Long-term progression in type II spinal muscular atrophy: A retrospective observational study 109
Prevalence of Spinal Muscular Atrophy in the Era of Disease-Modifying Therapies: An Italian Nationwide Survey 107
The Italian neuromuscular registry: a coordinated platform where patient organizations and clinicians collaborate for data collection and multiple usage 107
Patients on treatment with risdiplam in Italy: challenges in the interpretation of the real-world data 107
Pregnancy in the Era of Disease-Modifying Therapies for Spinal Muscular Atrophy: Considerations From a Case Report 105
Patient and parent oriented tools to assess health-related quality of life, activity of daily living and caregiver burden in SMA. Rome, 13 July 2019 104
Age and baseline values predict 12 and 24-month functional changes in type 2 SMA 103
Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy 102
Patterns of disease progression in type 2 and 3 SMA: Implications for clinical trials 101
Therapeutic Role of Nusinersen on Respiratory Progression in Pediatric Patients With Spinal Muscular Atrophy Type 2 and Nonambulant Type 3 101
Caregivers’ Expectations on Possible Functional Changes following Disease-Modifying Treatment in Type II and III Spinal Muscular Atrophy: A Comparative Study 99
Risdiplam in types 2 and 3 spinal muscular atrophy: A randomised, placebo-controlled, dose-finding trial followed by 24 months of treatment 98
Old measures and new scores in spinal muscular atrophy patients 97
Revised upper limb module for spinal muscular atrophy: 12 month changes 96
Risdiplam in Type 1 Spinal Muscular Atrophy 94
Sometimes they come back: New and old spinal muscular atrophy adults in the era of nusinersen 93
Prevalence of Spinal Muscular Atrophy in the Era of Disease-Modifying Therapies: An Italian Nationwide Survey 92
Diagnostic journey in Spinal Muscular Atrophy: Is it still an odyssey? 89
Spinal muscular atrophy — insights and challenges in the treatment era 89
Neonatal hypotonia and neuromuscular conditions 88
Therapy of encephalopathy with status epilepticus during sleep (ESES/CSWS syndrome): an update 87
Paediatric optic neuritis: factors leading to unfavourable outcome and relapses 86
Cognitive impairment in paediatric multiple sclerosis patients is not related to cortical lesions 84
Regional hippocampal involvement and cognitive impairment in pediatric multiple sclerosis 84
null 81
Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy 78
Epileptic Encephalopathies with Status Epilepticus during Sleep: New Techniques for Understanding Pathophysiology and Therapeutic Options 76
Totale 15.262
Salva come PNG Salva come JPEG
Categoria #
all - tutte 66.676
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 66.676
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022345 0 0 0 0 34 13 9 63 33 27 70 96
2022/20231.630 108 175 109 222 109 201 104 169 247 37 85 64
2023/20241.311 43 266 48 135 50 238 140 59 18 67 108 139
2024/20252.384 46 42 157 115 189 125 102 94 334 202 534 444
2025/20267.359 802 207 426 871 1.186 1.213 1.048 284 362 408 379 173
2026/20272.805 299 1.000 505 858 143 0 0 0 0 0 0 0
Totale 16.251